COMP <GO>
NKTX vs FHTX // EV/EBITDA & P/E VALUATION
Nkarta Inc. (NASDAQ) VS. Foghorn Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NKTX 0
— FHTX 2
■ METRIC PARITY
LAST: $1.56 (-6.02%) • MKT CAP: $118.9M
valuation
—
LAST: $2.08 (-0.48%) • MKT CAP: $124.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NKTX VS. FHTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NKTX | FHTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 36.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.2 | 30.4 | -10.25 | FHTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $118.9M | $124.1M | -$5.2M | FHTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NKTX REV | FHTX REV | NKTX GROSS % | FHTX GROSS % | NKTX FCF | FHTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $30.9M | — | — | -$89.9M | -$86.1M |
| FY 2024 | $0 | $22.6M | — | — | -$104.1M | -$101.3M |
| FY 2023 | $0 | $34.2M | — | — | -$86.2M | -$118.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NKTX // BETA —
FHTX // BETA —